SCHEMBL6795023

SCHEMBL6795023

Nc1ccc(OCc2nccs2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.48
TSHR P16473 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAOB P27338 6/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
MAOA P21397 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ACACB O00763 1/20 0.44
APP P05067 1/20 0.43
FBP1 P09467 1/20 0.41
LTA4H P09960 1/20 0.40
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
APAF1 O14727 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
NOS1 P29475 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16994919 0.82 TRPM8 (0.55) TSHRTDP1GAAMAPTRAB9A
SCHEMBL28758405 0.82 MAPT (0.49) CYP2C19TSHRMAOBGAAMAPT
SCHEMBL805346 0.81 RAB9A (0.49) MAOBMAPTMAOARAB9ASMN1; SMN2
SCHEMBL801225 0.81 ACACB (0.50) RAB9AL3MBTL1ACACBLTA4HKMT2A
SCHEMBL18605599 0.80 CYP3A4 (0.53) CYP2C19TSHRMAOBRAB9ASMN1; SMN2
SCHEMBL21024526 0.79 ACACB (0.51) TDP1MAPTRAB9ASMN1; SMN2L3MBTL1
SCHEMBL5757765 0.79 ACACB (0.41) RAB9ASMN1; SMN2L3MBTL1ACACBLTA4H
SCHEMBL21340753 0.78 APP (0.47) TSHRRAB9ASMN1; SMN2ACACBAPP
SCHEMBL16333928 0.78 RAB9A (0.40) CYP2C19TSHRMAOBMAPTRAB9A
SCHEMBL21340755 0.76 ACACB (0.46) TSHRMAPTRAB9ASMN1; SMN2ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3760633-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-01-06 EP disclosed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CYP2C19 1180/4885TSHR 1903/4885TDP1 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.